

ESMO 2016 INDUSTRY SATELLITE SYMPOSIUM

ADVANCED NSCLC: NAVIGATING THE REVOLUTION

MONDAY, OCTOBER 10, 2016 | 13:00-14:30

VENUE: BELLA CENTER, COPENHAGEN, DENMARK

ROOM: BRUSSELS AUDITORIUM

Top experts lead participants through case-based seminars on NSCLC novel therapies and treatment tactics in first-line settings and beyond at this CPD-accredited event. Lunch will be served.

PROGRAM AGENDA

13:00-13:05

Introduction

Johann F. Vansteenkiste, MD, PhD (Chair)

13:05-13:10

Navigating the Revolution: Goals of Therapy and Remaining Unmet Needs

Johann F. Vansteenkiste, MD, PhD

13:10-13:20

Optimizing First-Line Treatment for Patients Without Treatable Molecular Abnormalities

Egbert F. Smit, MD, PhD

13:20-13:35

The Patient With Advanced/Metastatic Adenocarcinoma

Enriqueta Felip, MD, PhD

13:35-13:50

The Patient With Advanced/Metastatic Squamous Cell Carcinoma

Joachim G. Aerts, MD, PhD

13:50-14:05

Optimizing the Treatment of Relapsed/Refractory NSCLC: Navigating a new Complexity in Treatment Selection and Patient Management

Maurice Perol, MD

14:05-14:25

The Patient With Relapsed/Refractory NSCLC

Marina C. Garassino MD

14:25-14:30

Conclusions

Johann F. Vansteenkiste, MD, PhD

CHAIR



Johann F. Vansteenkiste, MD, PhD

Professor of Internal Medicine, Department of Digestive Oncology, University of Leuven, Leuven, Belgium

PANELISTS



Joachim G. Aerts, MD, PhD

Associate Professor and Chief of Department of Thoracic Oncology, Erasmus University Medical Cancer Institute, Rotterdam, The Netherlands



Enriqueta Felip, MD, PhD

Head, Thoracic Tumors Group; Head, Medical Oncology Service of the Thoracic Tumors Committee, Vall d'Hebron Hospital, Barcelona, Spain



Marina C. Garassino, MD

Medical Consultant, Oncology Department, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy



Maurice Perol, MD

Head of Thoracic Oncology, Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France



Egbert F. Smit, MD, PhD

Professor of Pulmonary Medicine, The Netherlands Cancer Institute, Department of Thoracic Oncology and the Department of Pulmonary Diseases, Vrije Universiteit Medical Center, Amsterdam, The Netherlands

ACCREDITATION STATEMENT

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 1.5 continuing professional development credits (CPD).

Medscape
EDUCATION

This medical activity is supported by an independent educational sponsorship from 